Albumin-Binding Moieties Tune the Pharmacokinetics and Tumor Uptake of

Karim Obeid, Esther Olaniran Håkansson, Ekaterina Bezverkhniaia, Bobo Skillinghaug, Ulrika Rosenström, Panagiotis Kanellopoulos, Anna Orlova, Luke R Odell

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karim ObeidDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.

Esther Olaniran HåkanssonDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.

Ekaterina BezverkhniaiaDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-7699-5719

Bobo SkillinghaugDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.

Ulrika RosenströmDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-0817-8140

Panagiotis KanellopoulosDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-0617-3936

Anna OrlovaDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-6120-2683

Luke R OdellDepartment of Medicinal Chemistry, BMC Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-7658-5103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the gastrin-releasing peptide receptor (GRPR) is an established theranostic target across multiple cancers, many GRPR-targeting peptides undergo rapid renal clearance, limiting tumor uptake and therapeutic exposure. Albumin-binding moieties (ABMs) reversibly interact with serum albumin, prolonging systemic exposure and increasing the opportunity for tumor uptake. To examine how ABM structure and placement affect this behavior, we prepared four DOTA-functionalized GRPR-targeting conjugates, varying both ABM lipophilicity and position relative to the DOTA chelator. The conjugates were radiolabeled with lutetium-177 in radiochemical yields and purities of >98%. All radioconjugates retained GRPR-mediated uptake in PC-3 cells, exhibited subnanomolar receptor affinity and enhanced blood retention. [

Indexed as

albumin-binding moietyGastrin-releasing peptide receptorradiotheranostics

Identifiers

PMID42866464

DOI10.1021/acsmedchemlett.6c00338

PMCPMC13656281

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.